Evidence map›Paper›PMID 31568000›Full record

ArticleMedicine2019

Effectiveness, safety, and economic evaluation of adjuvant moxibustion therapy for aromatase inhibitor-induced arthralgia of postmenopausal breast cancer stage I to III patients: Study protocol for a prospective, randomized, assessor-blind, usual-care controlled, parallel-group, pilot clinical trial.

Seungwon Shin, Bo-Hyoung Jang, Seung-Hyeok Park, Jin-Wook Lee, Min Soo Chae, Namhoon Kim, Hae Sun Suh, Sola Han, Sun Young Min, Sun Kyung Baek and 2 more

Open access · goldAbstract readClinical Trial Protocol
In one paragraph

Article in Medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Seungwon ShinClinical Trial Center, Korean Medicine Hospital, Kyung Hee University.
Bo-Hyoung JangDepartment of Preventive Medicine, College of Korean Medicine, Kyung Hee University.
Seung-Hyeok ParkDepartment of Clinical Korean Medicine, Graduate School, Kyung Hee University, Seoul.
Jin-Wook LeeDepartment of Clinical Korean Medicine, Graduate School, Kyung Hee University, Seoul.
Min Soo ChaeDepartment of Clinical Korean Medicine, Graduate School, Kyung Hee University, Seoul.
Namhoon KimDepartment of Clinical Korean Medicine, Graduate School, Kyung Hee University, Seoul.
Hae Sun SuhPharmaceutical Economics, Outcomes Research and Policy, Pusan National University, Busan.
Sola HanCollege of Pharmacy, Pusan National University, Busan.
Sun Young MinDepartment of Surgery, College of Medicine, Kyung Hee University.
Sun Kyung BaekDepartment of Internal Medicine, College of Medicine, Kyung Hee University.
Yu Jin LimDepartment of Radiation Oncology, Kyung Hee University Medical Center, Kyung Hee University College of Medicine.
Deok-Sang HwangDepartment of Korean Obstetrics & Gynecology, College of Korean Medicine, Kyung Hee University, Seoul, Republic of Korea.
Kyung Hee University · KRPusan National University · KRKyung Hee University Medical Center · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThis study is a prospective, assessor-blinded, parallel-group, randomized controlled pilot trial to explore the effectiveness of 12-week adjuvant moxibustion therapy for arthralgia in menopausal females at stage I to III breast cancer on aromatase inhibitor (AI) administration, compared with those receiving usual care. METHODS/

designForty-six menopausal female patients with breast cancer who completed cancer therapy will be randomly allocated to either adjuvant moxibustion or usual care groups with a 1:1 allocation ratio. The intervention group will undergo 24 sessions of adjuvant moxibustion therapy with usual care for 12 weeks, whereas the control group will receive only usual care during the same period. The usual care consists of acetaminophen administration on demand and self-directed exercise education to manage AI-related joint pain. The primary outcome is the mean change of the worst pain level according to the Brief Pain Inventory-Short Form between the initial visit and the endpoint. The mean changes in depression, fatigue, and quality of life will also be compared between groups. Safety and pharmacoeconomic evaluations will also be included. DISCUSSION: Continuous variables will be compared by an independent t test or Wilcoxon rank-sum test between the adjuvant moxibustion and usual care groups. Adverse events will be analyzed using the chi-square or Fisher exact test. The statistical analysis will be performed by a 2-tailed test at a significance level of .05.

Indexed as

Aromatase InhibitorsArthralgiaBreast NeoplasmsMoxibustionAgedCost-Benefit AnalysisFemaleHealth Care CostsHumansMiddle AgedPilot ProjectsPostmenopauseRandomized Controlled Trials as TopicTreatment OutcomeAromatase Inhibitors

Identifiers

PMID31568000
PMCPMC6756724
OpenAlexW2979196035

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.